FORT MYERS, Fla. / Nov 06, 2025 / Business Wire / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences: Stephens Annual Investment Conference in Nashville, TN Company presentation on Wednesday, November 19, at 1:00 pm CT, accessible here Piper Sandler 37 th Annual Healthcare... Read More

Additional presentations to focus on liquid biopsy– MRD based detection and genomic profiling across solid tumors FORT MYERS, Fla. / Oct 30, 2025 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO) , a leading provider of oncology diagnostic solutions that enable precision medicine, will present new research at the International Society of Liquid Biopsy (ISLB) Annual Congress 2025 demonstrating high concordance between its... Read More

Third quarter total revenue increased 12% YoY to $188 million Clinical revenue grew 18%, or 15% excluding the Pathline acquisition NGS revenue increased 24% YoY and now accounts for nearly one-third of clinical revenue Re-affirming full-year guidance for revenue, net loss and adjusted EBITDA FORT MYERS, Fla. / Oct 28, 2025 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO) (the “ Company ” ), a leading provider of oncology... Read More

FORT MYERS, Fla. / Oct 14, 2025 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO) , a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the presentation of assay-relevant data, including interventional therapy trials in progress, to showcase how its molecular residual disease (MRD) assay may benefit pharmaceutical partners at the European Society for Medical Oncology (ESMO)... Read More

FORT MYERS, Fla. / Oct 07, 2025 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its third quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, October 28, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results... Read More

NeoGenomics wins summary judgment in patent infringement lawsuit against Natera; Court rules Natera’s patents are invalid for claiming ineligible subject matter NeoGenomics remains free to make, use, sell, and promote its RaDaR ST molecular residual disease (MRD) assay in the United States FORT MYERS, Fla. / Aug 29, 2025 / Business Wire / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions... Read More

New ctDNA-based test offers a flexible, guideline-driven solution for patients with advanced solid tumors when tissue is limited or unavailable FORT MYERS, Fla. / Jul 30, 2025 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO) , a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of NEO PanTracer™ LBx , a blood-based comprehensive genomic profiling (CGP) test,... Read More

Second Quarter Revenue Increased 10% to $181 million; Clinical Revenue Grew 16%, 13% excluding Pathline; Updates Full Year 2025 Guidance FORT MYERS, Fla. / Jul 29, 2025 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO) (the “ Company ” ), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its second-quarter results for the period ended June 30, 2025. Second Quarter 2025... Read More

FORT MYERS, Fla. / Jul 01, 2025 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and... Read More

FORT MYERS, Fla. / Jun 30, 2025 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO) , a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PanTracer™ Tissue, a next-generation solid tumor profiling assay, including the option to add testing for homologous recombination deficiency (HRD). These new options can provide faster, actionable insights to help physicians... Read More

FORT MYERS, Fla. / Jun 24, 2025 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO) , a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck. Dr. Green, a seasoned executive with extensive... Read More

The company expands precision oncology portfolio with new Paletrra spatial proteomics platform FORT MYERS, Fla. / May 28, 2025 / Business Wire / NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will debut its PanTracer™ Family, a comprehensive suite of genomic profiling tests for advanced solid tumors, at the 2025 American... Read More

FORT MYERS, Fla. / May 20, 2025 / Business Wire / NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading oncology testing services company, today announced the Company will participate in the following investor conferences: William Blair 45th Annual Growth Stock Conference in Chicago, IL Company presentation on Tuesday, June 3, at 1:00 pm ET, accessible here Jefferies Global Healthcare Conference in New... Read More

FORT MYERS, Fla. / May 01, 2025 / Business Wire / NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO) , a leading provider of oncology testing services, today announced that it has paid off in full the remaining $201.25 million in principal amount outstanding of its 1.25% Convertible Senior Notes with a maturity date of May 1, 2025, using cash on hand. About NeoGenomics, Inc. NeoGenomics, Inc. is a premier... Read More

FORT MYERS, Fla. and FREMONT, Calif. , April 29, 2025 /PRNewswire/ -- NeoGenomics, Inc. (Nasdaq:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, and Ultima Genomics, Inc., a developer of a revolutionary ultra-high throughput next-generation sequencing (NGS) platform, today announced a collaboration to use Ultima's UG 100™ sequencing platform and its ppmSeq™ technology to advance... Read More

Consolidated Revenue Increased 8% to $168 million FORT MYERS, Fla. / Apr 29, 2025 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO) (the “ Company ” ), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its first-quarter results for the period ended March 31, 2025. First Quarter 2025 Highlights As Compared To First Quarter 2024 Consolidated revenue increased 8% to $168 million... Read More

Additional Presentations Demonstrate Ongoing Commitment to Research & Innovation in Precision Oncology FORT MYERS, Fla. / Apr 22, 2025 / Business Wire / NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading provider of oncology testing services, today announced the analytical validation of its PanTracer LBx™ assay, a next-generation sequencing (NGS) liquid biopsy panel designed for comprehensive... Read More

FORT MYERS, Fla. / Apr 08, 2025 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its first quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, April 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and... Read More

Patients and physicians will benefit from access to NeoGenomics’ broad test menu and high-quality laboratory services in the Tri-state area FORT MYERS, Fla. / Apr 07, 2025 / Business Wire / NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced it has completed its previously announced acquisition of Pathline, LLC, a... Read More

FT. MYERS, Fla. / Apr 01, 2025 / Business Wire / NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO), a leading oncology testing services company, today announced that Tony Zook has officially assumed the role of Chief Executive Officer. A member of the company’s Board of Directors since 2023, Zook brings more than three decades of experience across diagnostics and biopharma, along with a proven track record of... Read More

Stone to drive lab operations, data solutions division and enterprise operations functions in addition to existing commercial responsibilities Leadership team aligned to support long term growth, profitability, and operational execution FT. MYERS, Fla. / Mar 18, 2025 / Business Wire / NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision... Read More

FT. MYERS, Fla. / Mar 10, 2025 / Business Wire / NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading provider of oncology testing services, today announced the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey. The acquisition strengthens NeoGenomics’ commercial presence in the Northeast U.S., expanding its service capabilities and accelerating growth in molecular... Read More

FT. MYERS, Fla. / Feb 24, 2025 / Business Wire / NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading oncology testing services company, today announced the Company will participate in the following investor conferences: TD Cowen 45 th Annual Health Care Conference in Boston, MA Fireside chat on Tuesday, March 4 at 1:50 p.m. ET, accessible here Leerink Partners Global Healthcare Conference in Miami, FL... Read More

Full Year Revenue Increased 12% to $661 million; Ninth Consecutive Quarter of Double-Digit Revenue Growth FORT MYERS, Fla. / Feb 18, 2025 / Business Wire / NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”) , a leading oncology testing services company, today announced its fourth-quarter and full year results for the period ended December 31, 2024. Fourth Quarter and Full Year 2024 Highlights Fourth quarter consolidated revenue... Read More

FORT MYERS, Fla. / Jan 29, 2025 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its fourth quarter and full year 2024 financial results prior to the open of the U.S. financial markets on Tuesday, February 18, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights.... Read More

Long-Range Plan reflects 12-13% revenue growth annually Presentation and webcast at 43 rd Annual J.P. Morgan Healthcare Conference today, Wednesday, January 15, at 1:30 p.m. PT / 4:30 p.m. ET FT. MYERS, Fla. / Jan 15, 2025 / Business Wire / NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO) , a leading oncology testing services company, today provided financial guidance for fiscal year 2025 and updated its... Read More

Chris Smith to retire effective April 1, 2025; Board Member Tony Zook named incoming CEO Company reaffirms Fiscal 2024 financial guidance FT. MYERS, Fla. / Jan 10, 2025 / Business Wire / NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading oncology testing services company, today announced that Chris Smith will retire as Chief Executive Officer (CEO) and board member effective April 1, 2025. Tony Zook,... Read More

FT. MYERS, Fla. / Dec 11, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, announced the recent publication of a new study in ESMO Open, demonstrating how circulating tumor DNA (ctDNA) in monitoring molecular residual disease (MRD) may enable earlier identification of disease recurrence for high-risk melanoma patients. Melanoma impacted over 100,000 patients in 2023; the... Read More

The company will showcase new insights into CNS lymphoma, myeloid malignancies, and gene fusions in acute myeloid leukemia FT. MYERS, Fla. / Dec 09, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will share its latest research on hematologic malignancies and the prognostic effects of microenvironment signatures in primary central nervous system (CNS) lymphoma at the 2024... Read More

FT. MYERS, Fla. / Nov 19, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present four abstracts at the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo in Vancouver, Canada, November 19-23 (booth #830). The research demonstrates how ctDNA and next-generation sequencing (NGS) can drive more personalized and accurate treatment options for cancer... Read More

FORT MYERS, Fla. / Nov 14, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced the appointment of Felicia Williams to its Board of Directors. “We are fortunate to welcome Felicia Williams to our board of directors, bringing her experience across the spectrum of finance, accounting, audit, and enterprise risk management to NeoGenomics,” said Lynn Tetrault,... Read More

FT. MYERS, Fla. / Nov 08, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will attend the Piper Sandler 36 th Annual Healthcare Conference. Members of the management team will participate in an in-person fireside chat on Thursday, Dec. 5, 2024, at 9:30 a.m. ET in New York City. The presentation will be webcast live and accessible online via this link . A replay will be... Read More

Adjusted EBITDA Improves 305%; Fifth Consecutive Quarter of Positive Adjusted EBITDA; Increasing FY Guidance to $37-$40 Million FORT MYERS, Fla. / Nov 05, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO) (the “ Company ” ), a leading oncology testing services company, today announced its third-quarter results for the period ended September 30, 2024. Third Quarter 2024 Highlights As Compared To Third Quarter 2023... Read More

FORT MYERS, Fla. / Oct 15, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its third quarter 2024 financial results prior to the open of the U.S. financial markets on Tuesday, Nov. 5, 2024. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may... Read More

New test fills unmet need for faster AML biomarker testing, expanding NeoGenomics’ broad oncology testing portfol io FT. MYERS, Fla. / Oct 08, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, announced today the launch of AML Express, a next-generation sequencing (NGS) assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia... Read More

Company will host business update call on Sept. 24, 2024, at 8:30 a.m. ET FT. MYERS, Fla. / Sep 23, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today issued the following statement in response to inquiries: NeoGenomics has cleared the feasibility stage with a new version of its RaDaR ® technology and has resolved litigation with Natera regarding RaDaR 1.0. The Company... Read More

FT. MYERS, Fla. / Sep 11, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present three studies at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, September 13-17 (booth #438). NeoGenomics' data offers key insights into circulating tumor DNA (ctDNA) analysis and next-generation sequencing (NGS), focusing on their role in early... Read More

FT. MYERS, Fla. / Aug 29, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will attend the Morgan Stanley 22nd Annual Global Healthcare Conference. Chris Smith, Chief Executive Officer, Jeff Sherman, Chief Financial Officer, and Warren Stone, Chief Commercial Officer, will participate in an in-person fireside chat on Friday, Sept. 6, 2024, at 10:45 a.m. ET in New York City.... Read More

Second Quarter Revenue Increased 12% to $165 Million Raising Revenue Guidance $655 to $667 Million and Adjusted EBITDA to $33 to $37 Million FORT MYERS, Fla. / Jul 29, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO) (the “ Company ” ), a leading oncology testing services company, today announced its second-quarter results for the period ended June 30, 2024. Second Quarter 2024 Highlights As Compared To Second Quarter... Read More

FT. MYERS, Fla. / Jul 09, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Monday, July 29, 2024. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights. The live webcast may be... Read More

FORT MYERS, Fla. / Jun 13, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that Fort Myers’ Mayor, Kevin Anderson, will be dedicating June as NeoGenomics’ Commitment to Cancer Month to honor cancer survivors and those currently living with cancer. Headquartered in Fort Myers, NeoGenomics serves over 600,000 patients each year and is on a mission to serve... Read More

FT. MYERS, Fla. / May 28, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will showcase its versatile lung solution and its COMPASS® Hematopathology Services portfolio at the American Society of Clinical Oncology (ASCO) conference in Chicago, May 31–June 4 (booth #31093). “With cancer cases on the rise, we’ve seen tremendous growth in FDA-approved targeted therapies and... Read More

First Quarter Revenue Increased 14% to $156 Million FORT MYERS, Fla. / Apr 30, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO) (the “ Company ” ) , a leading provider of oncology testing and global contract research services, today announced its first-quarter results for the period ended March 31, 2024. Highlights Consolidated revenue increased 14% to $156 million Clinical Services revenue increased 17% to $135... Read More

FT. MYERS, Fla. / Apr 18, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO) , a leading oncology testing services company, today announced two promotions within its senior leadership team, effective immediately. Warren Stone has been promoted to Chief Commercial Officer and will lead NeoGenomics’ clinical and pharma services commercial teams. Stone will be responsible for sales, marketing, pharma project management,... Read More

FT. MYERS, Fla. / Apr 09, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its first quarter 2024 financial results on Tuesday, April 30, 2024. Company management will host a webcast and conference call that morning at 8:30 a.m. Eastern Time to discuss financial results and recent highlights. The live webcast may be accessed by visiting... Read More

Insights from 11 Abstracts Highlight Key Findings Across the Oncology Care Spectrum FT. MYERS, Fla. / Mar 27, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, alongside research collaborators, will present key findings from 11 abstracts at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5-10 (booth #915), demonstrating its... Read More

FT. MYERS, Fla. / Mar 20, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today released its 2023 Environmental, Social, and Governance (ESG) Report highlighting progress toward building a more sustainable, diverse, and equitable company that delivers exceptional customer experience and advanced testing options. This inaugural report details the performance and management... Read More

FT. MYERS, Fla. / Mar 01, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced the company will participate in the upcoming TD Cowen 44th Annual Health Care Conference in Boston, Massachusetts. Members of NeoGenomics’ management team will participate in a fireside chat on Tuesday, March 5 th at 9:10 a.m. ET. A live and archived audio webcast of the presentation... Read More

Fourth Quarter Revenue Increased 12% to $156 million; Full Year Revenue Increased 16% to $592 million FORT MYERS, Fla. / Feb 20, 2024 / Business Wire / NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”) , a leading provider of oncology testing and global contract research services, today announced fourth quarter and full year 2023 results for the period ended December 31, 2023. Highlights Fourth quarter consolidated revenue... Read More

FORT MYERS, Fla. / Feb 01, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that the Company has signed the Working with Cancer Pledge . By taking the pledge, NeoGenomics demonstrates its commitment to supporting team members living with or caring for a loved one with cancer. Additionally, the company aims to open the conversation around cancer in the... Read More

FT. MYERS, Fla. / Jan 30, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 20, 2024. Company management will host a webcast and conference call that day at 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. The live webcast may be... Read More

FT. MYERS, Fla. / Jan 02, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced the company will participate in the upcoming 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco, California. Members of NeoGenomics’ management team will deliver a presentation followed by Q&A on Monday, January 8 th at 5:15 p.m. PT/8:15 p.m. ET. A live and archived audio... Read More

FORT MYERS, FL / ACCESSWIRE / December 28, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced that NeoGenomics Laboratories, Inc., a subsidiary of NeoGenomics Inc., will appeal the preliminary injunction issued by the United States District Court for the Middle District of North Carolina. The initial determination is that Natera, Inc. demonstrated a likelihood... Read More

FT. MYERS, FL / ACCESSWIRE / December 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced new data highlighting its RaDaR ® assay for minimal residual disease (MRD) will be presented at the 46 th annual San Antonio Breast Cancer Symposium (SABCS). RaDaR data will be presented during a Poster Spotlight Session featuring an updated analysis of the TRACER study, which assessed... Read More

FT. MYERS, FL / ACCESSWIRE / November 14, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced the company will participate in the upcoming Piper Sandler 35 th Annual Global Healthcare Conference in New York City. Members of NeoGenomics' management team will participate in a fireside chat on Wednesday, November 29 th at 9:00 a.m. Eastern Time. A live and archived audio webcast... Read More

Third Quarter Revenue Increased 18% to $152 Million FORT MYERS, FL / ACCESSWIRE / November 6, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the " Company " ), a leading oncology testing services company, today announced its third-quarter results for the period ended September 30, 2023 as compared to September 30, 2022. Third Quarter 2023 Highlights Q3 2023 Results Consolidated revenue increased 18% to $152 million Clinical Services... Read More

Neo Comprehensive™ - Heme Cancers is a large and comprehensive next-generation sequencing panel with broad coverage of genes associated with blood cancers Early-stage NSCLC Panel - a therapy selection panel providing a comprehensive overview of biomarkers for detecting early-stage lung cancer FT. MYERS, FL / ACCESSWIRE / October 24, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, announced... Read More

FT. MYERS, FL / ACCESSWIRE / October 17, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that it will report its third quarter 2023 financial results on Monday, November 6, 2023. Company management will host a webcast and conference call that day at 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. The live... Read More

Second Quarter Revenue Increased 18% to $147 Million FORT MYERS, FL / ACCESSWIRE / August 8, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the " Company " ), a leading oncology testing services company, today announced its second-quarter results for the period ended June 30, 2023 as compared to June 30, 2022. Highlights Consolidated revenue increased 18% to $147 million Clinical Services revenue increased 17% to $123 million... Read More

FT. MYERS, FL / ACCESSWIRE / July 27, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, announced today that the Molecular Diagnostics Services Program (MolDx) has conveyed coverage for the RaDaR® assay, a personalized liquid biopsy for minimal residual disease (MRD) and recurrence detection. Following this decision, effective as of March 24, 2023, the RaDaR assay is now covered for... Read More

FT. MYERS, FL / ACCESSWIRE / July 18, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023. Company management will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. The live webcast... Read More

FT. MYERS, FL / ACCESSWIRE / June 29, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced the appointment of Elizabeth Floegel, Neil Gunn, and Tony Zook to its Board of Directors. The Board has elected three new independent board members to join the board effective June 29, 2023. Elizabeth Floegel , Chief Information & Digital Officer of... Read More

FT. MYERS, FL / ACCESSWIRE / June 15, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that its RaDaR ® assay, a personalized liquid biopsy for minimal/molecular residual disease (MRD) and recurrence detection, has obtained its first pan-cancer commercial coverage by Blue Shield of California. Effective August 1, 2023, Blue Shield of... Read More

FT. MYERS, FL / ACCESSWIRE / June 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data in support of its RaDaR® assay for the detection of molecular residual disease (MRD) and recurrence in patients with high-risk hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Data from a... Read More

FT MYERS, FL / ACCESSWIRE / June 1, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced the company will be participating in the upcoming Goldman Sachs 44 th Annual Global Healthcare Conference in Dana Point, California. NeoGenomics' management is scheduled to participate in a fireside chat on Wednesday, June 14... Read More

FT. MYERS, FL / ACCESSWIRE / May 30, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data supporting its cancer tests and treatment guidance tools will be showcased in five poster presentations at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting taking place June 2-6 in Chicago, Illinois. "Together with our... Read More

First Quarter Revenue Increased 17% to $137 Million FORT MYERS, FL / ACCESSWIRE / May 8, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the " Company " ), a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced its first-quarter results for the period ended March 31, 2023. Highlights Consolidated revenue increased 17% to $137 million Clinical Services revenue... Read More

FT. MYERS, FL / ACCESSWIRE / May 3, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced the company will be participating in the upcoming BofA Securities 2023 Healthcare Conference in Las Vegas, Nevada. NeoGenomics' management is scheduled to participate in a fireside chat on Wednesday, May 10 th at 11:20 a.m.... Read More

FT. MYERS, FL / ACCESSWIRE / April 17, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that it will release its first quarter 2023 financial results on Monday, May 8, 2023. Along with the release, NeoGenomics will host a webcast and conference call that day at 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To... Read More

FT. MYERS, FL / ACCESSWIRE / April 11, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that members of its management team will participate in a fireside chat at the 22 nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, 2023 at 11:00am ET. A live audio webcast of the presentation will be... Read More

FT. MYERS, FL / ACCESSWIRE / April 6, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that the company and its collaborators will present a total of nine abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2023 taking place April 14-19, 2023 in Orlando, Florida. NeoGenomics, alongside collaborators, will present... Read More

FT. MYERS, FL / ACCESSWIRE / March 27, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that the Company will host an Investor Day on Tuesday, April 4, 2023, starting at 8:00 am ET. The event will feature a presentation by NeoGenomics' executive team members and conclude with a Q&A session. Pre-register for the event here. A live webcast of... Read More

Collaboration will leverage NeoGenomics’ large oncology diagnostic laboratory and Massive Bio’s proven-at-scale proprietary artificial intelligence platform to accelerate drug discovery and optimize patient selection for clinical trials. FT. MYERS, Fla. & NEW YORK / Mar 22, 2023 / Business Wire / Massive Bio, Inc. , a private... Read More

FT MYERS, FL / ACCESSWIRE / March 16, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today the commercial availability of the RaDaR ® assay, a liquid biopsy test for molecular/minimal residual disease (MRD). MRD is the trace amounts of circulating tumor DNA (ctDNA) that remain after surgery or other cancer treatment. The announcement comes after... Read More

FT. MYERS, FL / ACCESSWIRE / March 13, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today the expansion of their next-generation sequencing (NGS) portfolio of innovative products with the commercial availability of multiple tests, including Neo Comprehensive - Solid Tumor, a comprehensive genomic profile (CGP) for solid tumor cancers, and Neo... Read More

FT. MYERS, FL / ACCESSWIRE / February 28, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Chris Smith, chief executive officer of NeoGenomics, and Jeff Sherman, chief financial officer, will participate in a fireside chat at the 44th Annual Raymond James Institutional Investors Conference on Monday, March... Read More

Fourth Quarter Revenue Increased 10% to $139 million; Full Year Revenue Increased 5% to $510 million FORT MYERS, FL / ACCESSWIRE / February 23, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company") , a leading provider of oncology testing and global contract research services, today announced fourth quarter and full year 2022 results for the period ended December 31, 2022. Highlights Fourth quarter consolidated revenue... Read More

Newly-published data shows a strong link between tumor DNA circulating in blood and patient responses to investigational neoadjuvant treatment with immune therapies FT. MYERS, FL / ACCESSWIRE / February 6, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced results of a new study of the RaDaR ® assay in patients with muscle-invasive bladder... Read More

FT. MYERS, FL / ACCESSWIRE / February 6, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that it plans to release its fourth quarter and full year 2022, financial results on Thursday, February 23, 2023. The Company has scheduled a webcast and conference call to discuss their fourth quarter and full year 2022 results on Thursday, February 23,... Read More

Jeffrey S. Sherman Appointed Chief Financial Officer FT. MYERS, FL / ACCESSWIRE / December 5, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that Jeffrey S. Sherman will join the company as Chief Financial Officer, effective December 7, 2022. Mr. Sherman succeeds William Bonello who will remain with the Company to provide transition and... Read More

FT. MYERS, FL / ACCESSWIRE / December 5, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced, as required by the Nasdaq Listing Rules, equity inducement awards to Mr. Jeff Sherman, the company's new chief financial officer. As a material inducement to Mr. Sherman joining the company, and in accordance with Nasdaq Listing Rule 5635(c)(4), the... Read More